Benzinga | Feb 17, 2021 12:27PM EST

Oppenheimer Maintains Outperform on CRISPR Therapeutics, Raises Price Target to $187

Oppenheimer analyst Jay Olson maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and raises the price target from $165 to $187.